Free Trial

Chemours (NYSE:CC) Shares Up 5.6% - What's Next?

Chemours logo with Basic Materials background

Key Points

  • Chemours Company's stock rose by 5.6% to $17.70 amidst a significant drop in trading volume, reaching only 565,431 shares compared to an average of 3.5 million shares.
  • Analyst ratings for Chemours are mixed, with five analysts rating it a Buy, four a Hold, and revisions leading to a price target average of $17.38.
  • The company reported a quarterly EPS of $0.58, surpassing estimates and indicating a 5% revenue increase year-over-year, despite a negative net margin of 7.19%.
  • MarketBeat previews the top five stocks to own by October 1st.

Shares of The Chemours Company (NYSE:CC - Get Free Report) traded up 5.6% on Monday . The stock traded as high as $17.59 and last traded at $17.70. 565,431 shares changed hands during mid-day trading, a decline of 84% from the average session volume of 3,507,188 shares. The stock had previously closed at $16.75.

Analyst Ratings Changes

Several analysts have weighed in on the company. Zacks Research upgraded Chemours from a "strong sell" rating to a "hold" rating in a research report on Wednesday, August 27th. Mizuho boosted their price objective on Chemours from $13.00 to $16.00 and gave the company an "outperform" rating in a research report on Tuesday, July 15th. Barclays lowered their price objective on Chemours from $16.00 to $13.00 and set an "equal weight" rating for the company in a research report on Wednesday, May 28th. Royal Bank Of Canada boosted their price objective on Chemours from $14.00 to $15.00 and gave the company an "outperform" rating in a research report on Thursday, July 3rd. Finally, Wall Street Zen downgraded Chemours from a "hold" rating to a "sell" rating in a research report on Wednesday, May 21st. Five equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $17.38.

Get Our Latest Stock Analysis on Chemours

Chemours Trading Up 3.0%

The company has a debt-to-equity ratio of 17.16, a quick ratio of 0.83 and a current ratio of 1.68. The stock's 50-day simple moving average is $14.15 and its 200-day simple moving average is $12.74. The firm has a market capitalization of $2.58 billion, a PE ratio of -6.16 and a beta of 1.61.

Chemours (NYSE:CC - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The specialty chemicals company reported $0.58 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.46 by $0.12. The business had revenue of $1.62 billion for the quarter, compared to the consensus estimate of $1.57 billion. Chemours had a negative net margin of 7.19% and a positive return on equity of 35.14%. The company's quarterly revenue was up 5.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.38 EPS. Chemours has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, sell-side analysts expect that The Chemours Company will post 2.03 EPS for the current fiscal year.

Chemours Cuts Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, September 12th. Investors of record on Friday, August 15th were given a dividend of $0.0875 per share. This represents a $0.35 dividend on an annualized basis and a yield of 2.0%. The ex-dividend date of this dividend was Friday, August 15th. Chemours's dividend payout ratio (DPR) is -12.50%.

Insider Transactions at Chemours

In other Chemours news, CEO Denise Dignam purchased 4,068 shares of the stock in a transaction that occurred on Friday, August 8th. The stock was bought at an average cost of $12.06 per share, with a total value of $49,060.08. Following the transaction, the chief executive officer directly owned 191,546 shares in the company, valued at approximately $2,310,044.76. The trade was a 2.17% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.34% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its position in Chemours by 8.3% during the 1st quarter. Vanguard Group Inc. now owns 16,487,008 shares of the specialty chemicals company's stock valued at $223,069,000 after acquiring an additional 1,263,047 shares during the period. State Street Corp increased its holdings in shares of Chemours by 22.7% during the second quarter. State Street Corp now owns 6,114,328 shares of the specialty chemicals company's stock valued at $70,009,000 after acquiring an additional 1,131,682 shares in the last quarter. Ameriprise Financial Inc. increased its holdings in shares of Chemours by 21.6% during the second quarter. Ameriprise Financial Inc. now owns 4,216,064 shares of the specialty chemicals company's stock valued at $48,274,000 after acquiring an additional 748,052 shares in the last quarter. Millennium Management LLC increased its holdings in shares of Chemours by 60.4% during the first quarter. Millennium Management LLC now owns 4,022,782 shares of the specialty chemicals company's stock valued at $54,428,000 after acquiring an additional 1,515,520 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Chemours by 41.4% during the second quarter. Geode Capital Management LLC now owns 3,484,416 shares of the specialty chemicals company's stock valued at $39,901,000 after acquiring an additional 1,020,933 shares in the last quarter. 76.26% of the stock is owned by hedge funds and other institutional investors.

About Chemours

(Get Free Report)

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Chemours Right Now?

Before you consider Chemours, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemours wasn't on the list.

While Chemours currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

The AI-Proof Portfolio: 3 Stocks You Need to See
Markets Brace for Fed: What Investors Need to Know Before Wednesday
3 Biotech Stocks Under $5 With Huge Upside

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines